Pei Jiayu, Qiu Haifeng, Wang Wenjia, Wang Yulu, Wang Min, Wang Dian, Li Jing, Qin Yanru
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Department of Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Proteomics Clin Appl. 2025 Mar;19(2):e202300220. doi: 10.1002/prca.202300220. Epub 2025 Jan 26.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy which mainly consists of serous, mucinous, clear cell, and endometrioid subtypes. Due to the lack of classic symptoms at an early stage, EOC usually presented as advanced tumors with local and/or distant metastasis. Although a large portion of EOC was initially platinum-sensitive, most patients would acquire resistance to common chemotherapeutic agents. These aforementioned issues lead to a challenge for clinical treatments and unsatisfying outcomes. Previous studies have demonstrated the genetic features of EOC are hard to target and the alterations at DNA and RNA levels are not fully represented at the protein expression profiles which made it more complex. In recent years, a panel of studies attempted to explore the key proteins involved in the development and progression of EOC using high-throughput proteomic technologies. We herein summarized them to provide a full view of this topic.
上皮性卵巢癌（EOC）是最致命的妇科恶性肿瘤，主要包括浆液性、黏液性、透明细胞和子宫内膜样亚型。由于早期缺乏典型症状，EOC通常表现为伴有局部和/或远处转移的晚期肿瘤。尽管大部分EOC最初对铂敏感，但大多数患者会对常用化疗药物产生耐药性。上述问题给临床治疗带来了挑战，且治疗结果不尽人意。先前的研究表明，EOC的基因特征难以靶向，DNA和RNA水平的改变在蛋白质表达谱中并未完全体现，这使得情况更加复杂。近年来，一系列研究试图利用高通量蛋白质组学技术探索参与EOC发生和发展的关键蛋白质。我们在此对这些研究进行总结，以全面呈现该主题。
